About Solarea Bio
Solarea Bio is a company based in Cambridge (United States) founded in 2017 by Gerardo V Toledo. Solarea Bio has raised $37.24 million across 5 funding rounds from investors including Illumina, GISEV and S2G Ventures. Solarea Bio offers products and services including SBD111, SBD121, SBD3, SBD4, and Bondia. Solarea Bio operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Cambridge, United States
- Founders Gerardo V Toledo
- SectorsHealthcare
- Email••••••••
- Website solareabio.com
- Social LinkedIn
- Legal Name Solarea Bio, Inc.
- Total Equity Funding$37.24M (USD)
in 5 rounds
- Latest Funding Round$9.91M (USD), Series A
Nov 2025
- InvestorsIllumina
& 5 more
Products & Services of Solarea Bio
Solarea Bio offers a comprehensive portfolio of products and services, including SBD111, SBD121, SBD3, SBD4, and Bondia.
Clinically validated to slow bone loss in humans.
Developed for dietary needs in rheumatoid arthritis patients.
Targets dietary requirements for psoriatic arthritis management.
Addresses cellular aging through microbial innovations.
Beta launch for microbial solutions in health applications.
Funding Insights of Solarea Bio
Solarea Bio has successfully raised a total of $37.24M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $9.91 million completed in November 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $37.24M
- Total Rounds 5
- Last Round Series A — $9.91M
- Investors Count 6
All 5 funding rounds of Solarea Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2025 | $9.91M | Series A | – | – | – |
| Aug 2024 | $1M | Series B | – | – | – |
| May 2023 | $15M | Series B | – | S2G Ventures | |
| Sep 2020 | $11.33M | Series A | – | S2G Ventures, Bold Capital Partners | |
| Jul 2017 | – | Seed | – | Illumina | – |
6 investors in total: 6 institutional.
Investors in Solarea Bio
Solarea Bio has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Illumina, GISEV and S2G Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Stage agnostic venture capital firm | – | s2gventures.com | Chicago, United States | |
Early-stage life sciences and tech focused VC firm investing primarily in the US | – | boldcapitalpartners.com | Santa Monica, United States | |
Private investment firm focused on multiple sectors | – | vikingglobal.com | Greenwich, United States | |
Venture capital firm focused on pharmaceuticals, technology & biotechnology sectors | – | gg1978.com | Luxembourg, Luxembourg | |
Legal and family law services are provided by GISEV. | 2017 | gisev.com | Lugano, Switzerland | |
Developer of technologies for analysis of genetic variation and function | 1993 | illumina.com | San Diego, United States |
Investor details for Solarea Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Solarea Bio
10 people are tracked at Solarea Bio (3 in leadership, 7 in board & advisors).
| Name | Role | Group |
|---|---|---|
Gerardo V Toledo | Co-Founder & CEO | Leadership |
Mark Charbonneau | Vice President, R&d | Leadership |
David Easson Jr. | Chief Manufacturing Officer | Leadership |
Neal Bhadkamkar | Director | Board & advisors |
Michael Zuscik | Scientific Advisory Board Member | Board & advisors |
Anula Jayasuriya | Director | Board & advisors |
Susan Bukata | Scientific Advisory Board Member | Board & advisors |
Douglas P. Kiel | Scientific Advisory Board Member | Board & advisors |
Clifford Rosen | Scientific Advisory Board Member | Board & advisors |
Matthew Walker | Director | Board & advisors |
Complete people profiles for Solarea Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Solarea Bio
3 dated milestones of Solarea Bio across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Solarea Bio is founded.
- Funding First funding round.
- Funding Latest funding round, Series A, of $9.9M.
Competitors of Solarea Bio
Solarea Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| ironwoodpharma.com | 1998 | Cambridge, United States | $206.25M | 220 | Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | |
| chimerix.com | 2002 | Durham, United Kingdom | $95.23M | 72 | Antiviral oral therapeutics are developed for infectious diseases and cancers. |
Detailed competitors of Solarea Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Solarea Bio
Complete news archive for Solarea Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Solarea Bio
10 companies that operate in the same segment as Solarea Bio (Microbiome Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Biosolutions and enzymes are developed for biotechnology applications across industries. | 2000 | Bags Sword, Denmark | – | – | – | |
Pendulum is focused on developing advanced probiotic solutions. | 2012 | San Francisco, California, United States | USD 109.5 M | – | 55 | |
Gut microbiome insights, analytics, tests, and therapeutics are provided. | 2019 | Singapore, Singapore | USD 10.5 M | USD 1.37 M | – | |
Microbiome-based therapeutics for skin conditions like eczema are developed. | 2014 | Farmington, United States | USD 37.4 M | – | 12 | |
Engineered microbes are developed as programmable therapeutics for metabolic disorders. | 2013 | Cambridge, Massachusetts, United States | USD 34.4 M | USD 8 K | 1 | |
Therapeutics for infectious and autoimmune diseases are developed. | 2010 | Cambridge, Massachusetts, United States | USD 470.49 M | – | 71 | |
Biological drugs for skin and mucosa wound treatment are developed. | 2016 | Uppsala, Uppsala County, Sweden | USD 4.02 M | USD 1.12 M | – | |
Microbiome-based therapeutics for gut diseases are developed. | 2017 | Edinburgh, Scotland, United Kingdom | USD 72.96 M | – | 65 | |
The gut-brain axis is explored for therapeutic and nutritional innovations. | 2014 | New York, New York, United States | USD 479 M | – | 84 | |
Microbiome therapeutics are developed to address diverse diseases. | 2010 | Cambridge, Massachusetts, United States | USD 257.13 M | USD 789 K | 103 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Solarea Bio
Solarea Bio was founded in 2017.
Solarea Bio is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Gerardo V Toledo is the current CEO of Solarea Bio. They have also founded this company.
Solarea Bio is a funded company, having raised a total of $37.24M across 5 funding rounds to date.
Solarea Bio was founded in 2017 and is based in Cambridge, United States. Therapeutics based on the microbiome are developed, with probiotics sourced from natural origins. Services encompassing microbial genomics, metagenomics, and genome-wide metabolic models are provided to validate potential candidates. Operations are centered in the biotechnology sector, targeting health-related applications through microbial research.
Solarea Bio's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Solarea Bio offers SBD111, SBD121, SBD3, SBD4, and Bondia.
Solarea Bio has 6 investors. Key investors include Illumina, GISEV, S2G Ventures, Bold Capital Partners, and Viking Global Investors.
Solarea Bio operates through Solarea Bio, Inc..